Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1228756 | 0.81 | KCNH2 (0.62) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL1228758 | 0.81 | KCNH2 (0.62) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL16364722 | 0.81 | KCNH2 (0.62) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL30988920 | 0.80 | KCNH2 (0.60) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL1228893 | 0.80 | KCNH2 (0.60) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL1226572 | 0.80 | KCNH2 (0.60) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL1228891 | 0.80 | KCNH2 (0.60) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL12902222 | 0.78 | KCNH2 (0.60) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL1229419 | 0.78 | KCNH2 (0.77) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL16364417 | 0.76 | KCNH2 (0.72) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459570-B1 | NITROIMIDAZOOXAZINE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2014-12-24 | — | — | EP | disclosed |
| US-8293734-B2 | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | NOX5, NQO2, SIRT5 | KCNH2 2847/4885PTGS1 2481/4885SLC6A2 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.